Anti-Mouse CD22 Antibody [Cy34.1]

Background

CD22 is a B cell-specific type I transmembrane glycoprotein and a member of the immunoglobulin superfamily and sialic acid-binding Ig-like lectin (SIGLEC) family. As an inhibitory coreceptor of the B cell receptor (BCR), CD22 regulates B cell activation thresholds by binding to α2,6-linked sialic acid ligands via its extracellular domain. CD22 recruits the tyrosine phosphatase SHP-1 to immunoreceptor tyrosine-based inhibitory motifs (ITIMs) to inhibit BCR-induced Ca²⁺ signaling, thereby maintaining B cell immune tolerance. In mice, CD22 is crucial for the development of mature B cells, and its deficiency leads to impaired B cell function. Additionally, CD22 has emerged as a promising therapeutic target for autoimmune diseases and B cell malignancies, attracting attention for monoclonal antibody and CAR-T therapies.